Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Sherry Unabia
CONTACT
Lead
LTZ Therapeutics, Inc.
LTZ-232 is an engineered anti-EPCAM bispecific antibody designed to activate tumor-associated macrophages to phagocytose and kill tumor cells.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
